The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients currently on ALK targeted therapy.

Start Date13 May 2024

Sponsor / Collaborator

The Sidney Kimmel Comprehensive Cancer Center

100 Clinical Results associated with Prophylactic Neopeptide Vaccine(Sidney Kimmel Comprehensive Cancer Center )

100 Translational Medicine associated with Prophylactic Neopeptide Vaccine(Sidney Kimmel Comprehensive Cancer Center )

100 Patents (Medical) associated with Prophylactic Neopeptide Vaccine(Sidney Kimmel Comprehensive Cancer Center )

Literatures (Medical) associated with Prophylactic Neopeptide Vaccine(Sidney Kimmel Comprehensive Cancer Center )

01 Aug 2005·Antimicrobial Agents and ChemotherapyQ2 · MEDICINE

Neopeptide Antibiotics That Function as Opsonins and Membrane-Permeabilizing Agents for Gram-Negative Bacteria

Q2 · MEDICINE

Article

Author: Fridkin, Mati ; Giterman, Tal ; Yaakov, Hertzig ; Matityahou, Ariella ; Tsubery, Haim ; Ofek, Itzhak ; Cohen, Sofia

ABSTRACTWe suggest a novel approach to enhancing antimicrobial drug action by utilizing engineered peptide conjugates. Our most potent conjugates, [fMLF]PMBN and [fMLF]PMEN, are nonapeptides derived from polymyxin B's (PMB's) cyclic moiety (Thr-Dab-cyclo[Dab-Dab-d-Phe-Leu-Dab-Dab-Thr], where Dab is 2,4-diaminobutyric acid) and polymyxin E's (PME's) cyclic moiety (Thr-Dab-cyclo[Dab-Dab-d-Leu-Leu-Dab-Dab-Thr]), respectively, attached to a linear tail comprised of formyl-Met-Leu-Phe (fMLF). The cyclic part binds to gram-negative lipopolysaccharides, rendering the bacterial outer membrane permeable to hydrophobic antibiotics. The tail confers chemotactic and opsonic activities upon the conjugates. These two activities appear to be the basis for the conjugates' antibacterial activities. The conjugates are 8 to 10 times less toxic than the parent PMB or PME antibiotics. Fourteen of 18 mice lethally challenged with erythromycin-resistantKlebsiella pneumoniaesurvived following intraperitoneal administration of erythromycin and [fMLF]PMBN, whereas erythromycin or the peptide conjugate alone had no effect. Moreover, the clearance ofKlebsiellafrom blood was markedly enhanced by intravenous injection of the [fMLF]PMEN peptide conjugate compared to the clearance of the organism from the mice treated with buffer alone as a control and was similar to that achieved by the PME antibiotic. Blood clearance was also significantly enhanced by administration of PMEN either alone or in a mixture with fMLF, although the effect was less than that produced by the peptide conjugate. Since resistance to polymyxins, the parent molecules of the synthetic cyclic peptides, is rare, the emergence of bacteria resistant to the antimicrobial properties of the peptide conjugates may be precluded as well.

100 Deals associated with Prophylactic Neopeptide Vaccine(Sidney Kimmel Comprehensive Cancer Center )

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
ALK positive Non-Small Cell Lung Cancer	Phase 2	US	The Sidney Kimmel Comprehensive Cancer Center	13 May 2024
metastatic non-small cell lung cancer	Phase 2	US	The Sidney Kimmel Comprehensive Cancer Center	13 May 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Prophylactic Neopeptide Vaccine(Sidney Kimmel Comprehensive Cancer Center )

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation